Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening diseases in critically ill patients. Although pathophysiology of ALI/ARDS has been investigated in many studies, effective therapeutic strategies are still limited. Mesenchymal stem cell (MSC)-based therapy is emerging as a promising therapeutic intervention for patients with ALI. During the last two decades, researchers have focused on the efficacy and mechanism of MSC application in ALI animal models. MSC derived from variant resources exhibited therapeutic effects in preclinical studies of ALI with different mechanisms. Based on this, clinical studies on MSC treatment in ALI/ARDS has been tried recently, especially in COVID-19 caused lung injury. Emerging clinical trials of MSCs in treating COVID-19-related conditions have been registered in past two years. The advantages and potential of MSCs in the defense against COVID-19-related ALI or ARDS have been confirmed. This review provides a brief overview of recent research progress in MSC-based therapies in preclinical study and clinical trials in ALI treatment, as well as the underlying mechanisms.
Keyphrases
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- mesenchymal stem cells
- mechanical ventilation
- coronavirus disease
- clinical trial
- sars cov
- umbilical cord
- cell therapy
- randomized controlled trial
- lipopolysaccharide induced
- lps induced
- bone marrow
- intensive care unit
- respiratory syndrome coronavirus
- stem cells
- inflammatory response
- case control
- phase iii